Regulatory filing with China’s National Medical Products Administration requests approval for Jublia for treatment of onychomycosis, a fungal toenail infection. San Diego, CA, USA – March 9, 2021 – HUYABIO International (HUYABIO), the leader in accelerating global development of China’s pharmaceutical innovations, today announced that its joint venture with Tianjin Institute of Pharmaceutical Research has … Continue reading HUYABIO International and Tianjin Institute of Pharmaceutical Research Joint Venture Submits Chinese New Drug Application for Efinaconazole as Jublia^™